Boston Scientific (BSX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
18 Mar, 2026Voting matters and shareholder proposals
Election of ten directors is proposed, with board recommending a vote for each nominee.
Advisory vote on executive compensation is recommended for approval.
Ratification of Ernst & Young LLP as independent auditor for 2026 fiscal year is recommended.
Amendments to the Employee Stock Purchase Plan to increase reserved shares are proposed.
Amendments to the Certificate of Incorporation to remove supermajority voting, provide officer exculpation, and allow 25% shareholders to call special meetings are recommended.
Board recommends voting against a shareholder proposal to give shareholders the ability to call special meetings.
Board of directors and corporate governance
Ten director nominees are listed for election at the annual meeting.
Proposed amendments would enhance shareholder rights by lowering thresholds for calling special meetings.
Executive compensation and say-on-pay
Advisory vote on executive compensation for named executive officers is included, with board support.
Latest events from Boston Scientific
- Q1 2026 delivered double-digit sales growth, strong EPS, and major acquisitions amid segment headwinds.BSX
Q1 20261 May 2026 - Directors re-elected, strong growth reported, and shareholder meeting threshold proposals failed.BSX
AGM 202630 Apr 2026 - $15B acquisition expands into high-growth vascular markets, targeting double-digit EPS growth.BSX
M&A announcement14 Apr 2026 - Double-digit sales and EPS growth in 2025; 2026 outlook strong with innovation and margin expansion.BSX
Q4 202513 Apr 2026 - Clinical trial successes and innovation pipeline support major market and guideline expansion.BSX
American College of Cardiology 75th Annual Scientific Session and Expo29 Mar 2026 - 2025 performance exceeded targets, driving pay-for-performance and governance reforms.BSX
Proxy Filing18 Mar 2026 - Shareholders to vote on director elections, executive pay, auditor, and major governance changes.BSX
Proxy Filing6 Mar 2026 - Double-digit growth, innovation in EP/PFA, and portfolio expansion drive strong outlook.BSX
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Q2 net sales up 14.5% to $4.12B, adjusted EPS $0.62, and guidance raised for 2024.BSX
Q2 20243 Feb 2026